Tobinco Pharmaceuticals Set To Produce Covid-19 Treatment Drugs For Ghana With $5 Million

As nations around the globe endeavor to stay on the management of the COVID-19 malady, which has infected more than 3.5million around the world, Ghana has increased its determination to keep up its leadership of the infection.

The nation is set to start the production of Hydroxychloroquine and Azithromycin, two medications that have demonstrated compelling for the treatment of COVID-19 patients.

The infection, which has been pronounced a worldwide pandemic, has no predetermined fix or antibodies however people diagnosed positive can be managed and treated.

Read Also:  NSMQ 2020 Postponed Till Further Notice

The production is a joint effort between Tobinco Pharmaceutical Group of Companies and the EXIM Bank Ghana that has seen the Bank contract of  $5 million facilities to Entrance Pharmaceuticals and Research Center, an individual from the Tobinco.

Affirming the news on Accra-based Okay FM, Monday, Chief Executive Officer (CEO) of the Tobinco Pharmaceutical Group of Companie, Samuel Amo Tobbin said the two medications have been distinguished as a potential treatment for the infection and will be produced till the pandemic is over.

Board Chairman of the Bank, Kwadwo Boateng Genfi additionally said "Ghana Exim was profoundly dazzled with Tobinco's usage of a past contract reached out to the group and, along these lines, was prepared to propel another $5 million to help tackle the pandemic in the nation,'' during a visit by individuals from the Exim Bank Credit Subcommittee to the Entrance Pharmaceuticals and Research Center

Post a Comment